[Asia Economy Reporter Kum Boryeong] Cha Biotech announced on the 15th that it has acquired a Japanese patent related to 'Improved Umbilical Cord-Derived Adherent Stem Cells, Their Manufacturing Method, and Their Use.'
Cha Biotech stated, "The improved umbilical cord-derived adherent stem cells have anti-inflammatory effects, vascular regeneration effects, or nerve regeneration effects, and are usefully applied in pharmaceutical compositions or cell therapies for the treatment or prevention of various diseases." They added, "In the future, when conducting regenerative medicine business including clinical trials of cell therapies in Japan, we plan to utilize this to establish a technical foundation for new drug substances and manufacturing methods, and to secure a preemptive position through patent rights protection."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

